Edition:
United States

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

129.75SEK
15 Dec 2017
Change (% chg)

0.25kr (+0.19%)
Prev Close
129.50kr
Open
130.00kr
Day's High
130.00kr
Day's Low
128.25kr
Volume
19,219
Avg. Vol
29,146
52-wk High
145.75kr
52-wk Low
103.00kr

Select another date:

Thu, Oct 26 2017

BRIEF-Camurus Q3 operating loss widens to SEK ‍67.1​ million

* Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO

BRIEF-Camurus and Braeburn announce submission of NDA for long-acting buprenorphine (CAM2038) for opioid use disorder

* CAMURUS AND BRAEBURN ANNOUNCE SUBMISSION OF NDA FOR LONG-ACTING BUPRENORPHINE (CAM2038) FOR OPIOID USE DISORDER

BRIEF-Camurus Q2 operating loss widens to SEK ‍58.7​ mln

* Q2 REVENUE SEK ‍19.1​ MILLION VERSUS SEK 25.8 MILLION YEAR AGO

BRIEF-Camurus and Braeburn Pharma announce phase 2 results for long-acting Buprenorphine in opioid dependent patients with chronic pain

* Camurus and Braeburn Pharmaceuticals announce topline phase 2 results for long-acting buprenorphine in opioid dependent patients with chronic pain

BRIEF-Trial results suggest that Camurus' CAM2038 formulations would be effective in reducing illicit opioid use, relapse

* LONG-ACTING BUPRENORPHINE BLOCKS OPIOID EFFECTS AND SUPPRESSES WITHDRAWAL SYMPTOMS IN ADULTS WITH OPIOID USE DISORDER

Select another date: